Camille Roukoz

Dr. Camille Roukoz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSalvatore Cozzi
Salvatore Cozzi
SGSebastiano Finocchi Ghersi
Sebastiano Finocchi Ghersi
FTFrancesca Tava
Francesca Tava
LBLilia Bardoscia
Lilia Bardoscia
MNMasoumeh Najafi
Masoumeh Najafi
CTCecilia Taverna
Cecilia Taverna
Introduction: Considering the increasing number of conservative surgeries (quadrantectomies) for primary breast carcinoma, especially in the early stages, often followed by adjuvant radiotherapy, the incidence of radiation-associated angiosarcoma (RAS) is expected to rise in the coming decades, and it will represent a clinical and therapeutic challenge, as limited data are available due to the rarity and heterogeneity of the disease. Though the prognosis of these patients is poor, a number of clinical and pathological factors can be evaluated to better understand the course of RAS. The aim of this systematic review is to explore the available clinical-pathological, therapeutic, and prognostic data regarding RAS to evaluate its occurrence, diagnosis, treatment, and outcomes. Method: RAS clinical data were identified by a systematic review conducted in five different databases (Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane). Only RAS works published in English, with access to the full manuscript text, and with clear results, were considered as eligible. Results: We considered 52 papers comprising 319 RAS cases. The patient age at diagnosis ranged from 37 to 93 years, with most cases occurring from 5 to 10 years after breast irradiation. The most common clinical presentation was an aggressive development of macules, papules, or erythematous-violaceous skin discoloration at the site of previous radiation treatment for primary breast carcinoma. Complete surgical excision appeared to be the first-line treatment of the disease, in some cases followed by adjuvant local and/or systemic therapies. Despite different treatments, local recurrence rates ranged from 40% to 90%, leading to negative outcomes and poor prognosis for patients. Conclusion: Although the literature is limited and the data are heterogeneous and contentious, our review aims to highlight the importance of early diagnosis, multimodal treatment, and long-term follow-up of RAS in order to limit and prevent the aggressiveness of this neoplasm.

Verified
Journal Article
Open access
PDF file
AJAmin Jahanbakhshi
Amin Jahanbakhshi
MNMasoumeh Najafi
Masoumeh Najafi
MGMarzieh Gomar
Marzieh Gomar
PCPatrizia Ciammella
Patrizia Ciammella
MRMaria Paola Ruggieri
Maria Paola Ruggieri
SCSalvatore Cozzi
Salvatore Cozzi
Background: Meningiomas are the most prevalent benign intracranial tumors. When they are of the invasive subtypes, i.e., grades II and III, they can recur rapidly and present a real challenge for physicians. This study is focused on the use of stereotactic radiosurgery to manage high-grade meningiomas. Method: Medline via PubMed was searched from inception to December 2022 to retrieve studies on stereotactic radiation therapy for patients with grade II-III meningiomas. This study was conducted under PRISMA guidelines. Result: A total of 29 articles involving 1446 patients with grade II-III meningiomas treated with stereotactic radiation therapy were included in the present study. Of these studies, 11 were conducted exclusively on patients with atypical meningiomas (grade II), 1 targeted anaplastic meningiomas (grade III), and 17 articles were carried out on both grade II and III meningiomas. The pooled 1, 2, 3, 5, and 10-year overall survival (OS) of grade II meningiomas was 0.96 [p < 0.01], 0.89 [p = 0.01], 0.90 [p = 0.09], 0.81 [p < 0.01], and 0.66 [p = 0.55], respectively. The pooled 2, 5, and 10-year OS of grade III meningiomas was 0.64 [p = 0.01], 0.41 [p = 0.01], and 0.19 [p < 0.01], respectively. Conclusions: Although long-term prospective studies are still required, the outcomes of stereotactic radiation therapy appear promising regarding overall outcome and progression-free survival.

18 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CRCamille Roukoz
Camille Roukoz
ALAmina Lazrek
Amina Lazrek
LBLilia Bardoscia
Lilia Bardoscia
GRGiuseppe Rubini
Giuseppe Rubini
CLChieh-Min Liu
Chieh-Min Liu
SCSalvatore Cozzi
Salvatore Cozzi
Background: Radical prostatectomy (RP) is one possible curative treatment for localized prostate cancer. Despite that, up to 40% of patients will later relapse. Currently, post-operative radiotherapy (PORT) courses deliver 1.8–2 Gy daily to reach a total dose ranging between 64 and 74 Gy, completed in 7–8 weeks. Several articles reported encouraging data in terms of the effectiveness and the related toxicities using hypofractionation schedules. The objective of the present systematic review was to evaluate the clinical outcomes and toxicity of the use of hypofractionation in adjuvant/salvage prostate cancer treatments. Methods: Medline was searched via PubMed and Scopus from inception to July 2024 to retrieve studies on hypofractionation in adjuvant/salvage prostate cancer treatments. This study was conducted under PRISMA guidelines. Results: A total of 139 articles were identified from the initial search. Subsequently, the 139 studies were reviewed by title and Ninety-five studies were excluded due to being either abstracts or articles not available in English. In the second step, the full texts of 44 studies were reviewed. Eleven studies were excluded for being reviews, study protocols, or focused on SBRT treatments. Finally, 33 studies were included in our analysis, with a total number of 4269 patients. Of the 33 selected studies, 20 were retrospective trials and 11 were phase I/II prospective trials, while 2 studies were prospective phase III trials. The follow-up ranged from 18 to 217 months. Failure-free survival, for those with the longer follow-up, ranged between 85% and 91% at 3 years, 47 and 78.6% at 5 years and 51.5% at 10 years. Genitourinary (GU) and gastrointestinal acute toxicity was mild to moderate with similar rates across the normofractionated and hypofractionated groups. Acute grade-3 GU toxicity events were unusual, occurring in less than 4% of the cases overall. Conclusion: The present study is the first systematic review of the literature that includes the first two randomized phase III studies published in the literature. Hypofractionated treatment has been shown to be safe, effective, with moderate toxicity and not inferior to conventional RT, with good biochemical control rates.

30 January 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ALAmina Lazrek
Amina Lazrek
SGSebastiano Finocchi Ghersi
Sebastiano Finocchi Ghersi
APAdeline Petre
Adeline Petre
SHSarah Houabes
Sarah Houabes
ASAnne-Agathe Serre
Anne-Agathe Serre
SCSalvatore Cozzi
Salvatore Cozzi
Introduction: Prostate cancer remains a prevalent malignancy among men, often necessitating innovative therapeutic strategies for effective management of recurrent cases. This article examines the critical role of a biodegradable hydrogel spacer, which creates a temporary interspace between the prostate and the rectum, thus reducing radiation exposure to healthy tissues.Case description: We present a case of a man with a history of intermediate-risk prostate adenocarcinoma initially treated with external beam radiotherapy in 2015. Despite initial remission, the patient experienced a rise in prostate-specific antigen (PSA) levels indicative of local recurrence in 2022. Salvage treatment with iodine-125 brachytherapy, preceded by the placement of a rectal spacer in January 2024, resulted in a significant reduction of PSA levels. The patient remains asymptomatic with no urinary or gastrointestinal complications 6 months after the salvage treatment.Discussion: This case illustrates the complexities in managing recurrent prostate cancer and the evolving role of reirradiation strategies. Salvage iodine-125 brachytherapy with the placement of a rectal spacer provided precise radiation delivery while minimizing rectal toxicities. The significant biochemical response observed underscores the efficacy of this approach in controlling disease progression. The rectal spacer enhances treatment safety by reducing radiation exposure to adjacent tissues, highlighting its importance in reirradiation protocols. This case contributes to the growing evidence supporting the rectal spacer’s role in enhancing the safety and efficacy of salvage brachytherapy for recurrent prostate cancer.Conclusions: Our experience advocates for the integration of a hydrogel rectal spacer as a valuable tool in prostate cancer reirradiation protocols, offering a strategic approach to optimize treatment safety by minimizing rectal toxicity.

18 October 2025 in European Urology Open Science
Verified
Journal Article
Open access
SCSalvatore Cozzi
Salvatore Cozzi
CRCamille Roukoz
Camille Roukoz
TZThomas Zilli
Thomas Zilli
By delivering targeted radiation to tumor cells with a minimal impact on healthy tissues, radioligand therapy (RLT) has become an established treatment for metastatic castration-resistant prostate cancer. Its combination with external beam radiotherapy (EBRT) offers potential synergy: EBRT achieves high-dose, conformal local irradiation, whereas RLT can target systemic disease. This complementary approach could delay disease progression and improve local control, particularly in the oligometastatic setting. Emerging evidence supports the feasibility and safety of this approach, but prospective data remain limited. We summarize the current clinical landscape for this setting and pivotal ongoing trials investigating RLT + EBRT combinations for metachronous oligometastatic hormone-sensitive prostate cancer, with a focus on rationale, treatment sequencing, and future directions. In metastatic prostate cancer, the disease may spread to only a few sites in some cases, which is called oligometastatic prostate cancer (omPC). We describe a combined treatment strategy for patients with omPC. Radiotherapy targets tumors in specific areas, while radioligand therapy (which involves injection of a radioactive drug) can reach cancer cells throughout the body. Combining these two treatments may improve cancer control for both the primary tumor and metastases.

14 June 2025 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
CCChiara Casale
Chiara Casale
MSMarie-Pierre Sunyach
Marie-Pierre Sunyach
SCSalvatore Cozzi
Salvatore Cozzi
CRCamille Roukoz
Camille Roukoz